Literature DB >> 29622102

Daratumumab for POEMS Syndrome.

Maliha Khan1, Katie Stone1, Frits van Rhee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29622102     DOI： 10.1016/j.mayocp.2018.02.001

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  8 in total

1.  First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS).

Authors:  Omur Gokmen Sevindik; Yasa Gul Mutlu; Berrin Balik Aydin; Istemi Serin
Journal:  Hemasphere       Date:  2022-06-17

2.  Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.

Authors:  Ankit Kansagra; Angela Dispenzieri; Raphael Fraser; Noel Estrada-Merly; Surbhi Sidana; Taiga Nishihori; Doris K Hansen; Larry D Anderson; Rahul Banerjee; Naresh Bumma; Binod Dhakal; Jack Khouri; Heather Landau; Cindy Lee; Hira Mian; Sunita Nathan; Bipin Savani; Shaji Kumar; Muzaffar Qazilbash; Nina Shah; Anita D'Souza
Journal:  Blood Adv       Date:  2022-07-12

3.  Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.

Authors:  Maria Gavriatopoulou; Ioannis Ntanasis-Stathopoulos; Despina Fotiou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Nikolaos Kanellias; Maria Roussou; Ioanna Dialoupi; Panagiotis Malandrakis; Foteini Theodorakakou; Efstathios Kastritis; Evangelos Terpos; Meletios-Athanasios Dimopoulos
Journal:  Hemasphere       Date:  2020-05-21

4.  Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.

Authors:  Tomoki Suichi; Sonoko Misawa; Kengo Nagashima; Yasunori Sato; Yuta Iwai; Kanako Katayama; Yukari Sekiguchi; Kazumoto Shibuya; Hiroshi Amino; Yo-Ichi Suzuki; Atsuko Tsuneyama; Keigo Nakamura; Satoshi Kuwabara
Journal:  Intern Med       Date:  2020-02-01       Impact factor: 1.271

Review 5.  Update on the POEMS syndrome.

Authors:  Yu Ri Kim
Journal:  Blood Res       Date:  2022-04-30

6.  Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.

Authors:  Ryutaro Taenaka; Sakurako Shimokawa; Ayako Katayama; Toshihiko Nagao; Teppei Obara; Naoaki Nishimura; Atsushi Tsujimoto; Kentaro Kohno; Kenichi Aoki; Ryosuke Ogawa
Journal:  J Med Case Rep       Date:  2022-08-18

7.  Daratumumab-bortezomib-dexamethasone use in relapsed POEMS syndrome.

Authors:  Jahanzaib Khwaja; Ryan Keh; Duncan Smyth; Michael Peter Lunn; Shirley D'Sa; Jonathan Sive
Journal:  EJHaem       Date:  2022-06-05

Review 8.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.